Summary & Overview
HCPCS J9255: Methotrexate Injection, 50 mg (Accord)
HCPCS Level II code J9255 denotes a 50 mg injectable dose of methotrexate (brand: accord), identified as not therapeutically equivalent to J9260. This product-level billing code is used when administering methotrexate by injection in outpatient and ambulatory infusion settings and is relevant to oncology, rheumatology, and certain autoimmune disease management. Nationally, biologic and chemotherapeutic drug coding matters for accurate clinical documentation, inventory control, and payer reimbursement consistency.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context and common sites of service for J9255, along with payer coverage considerations and typical billing practice features. The publication outlines benchmarks and policy updates where available, clarifies the clinical role of methotrexate injections relative to other injectable formulations, and highlights coding distinctions tied to therapeutic equivalence language in the descriptor.
This summary equips billing managers, coding professionals, and revenue leaders with the essential information needed to recognize when J9255 applies, what settings it is commonly billed in, and which national payers are typically involved. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J9255 represents an injection of methotrexate (accord), 50 mg, specified as not therapeutically equivalent to J9260. This code denotes a single injectable product identity and strength for methotrexate supplied for parenteral administration.
-
Service type: Injectable biologic/chemotherapy agent administered by parenteral injection
-
Typical site of service: Hospital outpatient department, physician office, infusion center, or other clinic settings where parenteral chemotherapy or disease-modifying injections are provided
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 54-year-old female with rheumatoid arthritis who has an inadequate response to oral disease-modifying antirheumatic drugs presents to an outpatient infusion clinic for parenteral methotrexate therapy. The clinician elects to administer J9255 (methotrexate, 50 mg vial, branded as Accord) as an intramuscular or subcutaneous injection. The workflow includes pre-procedure verification of indication and weight, medication reconciliation, allergy screening, informed consent for injectable therapy, site preparation, administration of the single-dose vial per manufacturer and facility policy, post-injection observation for immediate adverse reactions, documentation of lot number and vial disposal (including use of modifier JW if partial vial waste is discarded), and scheduling of follow-up rheumatology visits and laboratory monitoring (CBC, LFTs, renal function) per standard methotrexate monitoring protocols. Typical site of service is an outpatient clinic, physician office, or community infusion center. Common patient considerations include teratogenic risk counseling for patients of childbearing potential, folic acid supplementation counseling, and documentation of clinical rationale when higher-than-usual doses or additional services are provided.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier required |